Akeso reports another Phase 3 win for PD-1xVEGF approach in lung cancer
Akeso said its PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a Phase 3 study in lung cancer patients in China. The readout marks the third late-stage win for...
View ArticleAscletis posts puzzling Phase 1 update on obesity pill
Ascletis Pharma’s obesity pill was less effective at its high dose than at lower doses in an early-stage trial, the biotech said Tuesday. While this doesn’t preclude further development of ASC30 ...
View ArticleGenentech vet launches ADC startup with $20M
A Bay Area protein design startup wants to build more potent antibody-drug conjugates, and is starting with $20 million in seed funding. The company, Synthetic Design Lab, was founded by former...
View ArticleTelenutrition startup Nourish raises $70M
Telenutrition platform Nourish has raised $70 million and reached profitability a little more than a year after its last raise as food medicine startups get a boost under the Trump administration....
View ArticleFDA asks Novavax for post-marketing data of its Covid vaccine, delaying approval
The FDA has asked Novavax to commit to producing post-marketing data of its Covid vaccine, the clearest example yet that the goalposts have changed for vaccine makers under HHS Secretary Robert F....
View ArticleWith aims to become a 'generational biotech,' Zealand Pharma hires Lilly...
Fresh off a splashy obesity deal, Zealand Pharma is doubling down on its R&D ambitions with a new chief scientific officer. The Copenhagen-based biotech, which is partnered with Roche and...
View ArticleChina’s biotech market is staging a comeback that US biotech can only wish for
China’s biopharmaceutical sector is showing signs of revival from its post-pandemic slump, even as its US counterpart remains in a rut. Buoyed by licensing deals, improving company fundamentals and...
View ArticleVeraxa makes a SPAC deal; Illumina discloses layoffs
Plus, news about Innate Pharma, Sanofi, Claris Ventures and Rezolute: A rare SPAC deal: At a time when public markets are challenging for IPOs, a Swiss biotech plans to merge with ...
View ArticleTop pharma companies increased lobbying spend at start of 2025
Pfizer, Novartis, Amgen, Eli Lilly and Johnson & Johnson were the top congressional lobbying spenders among the major biopharma companies, as the industry faces a tumultuous environment in which...
View ArticleVaccine makers stand by their investments despite US headwinds
WASHINGTON — Representatives from large vaccine makers say they are committed to their pipelines, despite a new wave of scrutiny in the US that risks diminishing a major market. On a panel at the World...
View ArticleEurope 'falling behind' on drug R&D and manufacturing investments:...
AstraZeneca CEO Pascal Soriot called on Europe to step up investments and “protect its health sovereignty" as it falls behind the US on spending. His comments echo calls from other pharma CEOs who are...
View ArticleRoche Q1 earnings: CEO warns that tariffs could impact dealmaking
Roche said that its future dealmaking could be impacted by potential tariffs on pharmaceuticals. “If there are questions around tariffs, it will be more difficult to make financial sense of any M&A...
View ArticleSanofi Q1 earnings: Altuviiio closing in on blockbuster status, Dupixent...
Sanofi posted a strong set of first-quarter results Thursday morning, with its recombinant factor drug Altuviiio on track to become a blockbuster drug and its crown jewel Dupixent continuing to draw...
View ArticleMerck Q1 earnings: Gardasil sales hit by China market pressure
Sales of Merck’s HPV vaccine plummeted 41% in the first quarter, as the company continues to deal with lower demand in China. Gardasil is Merck’s second-biggest product behind its megablockbuster...
View ArticleRoche takes steps to protect itself from tariffs, while Sanofi hangs back
Roche and Sanofi said on Thursday morning they have been running scenarios on how US and other tariffs could potentially impact their respective businesses. However, while Roche has detailed specific...
View ArticleThermo Fisher buckles up for US-China trade war, budgets $2B to ease impact
Thermo Fisher Scientific has warned it could lose out on nearly $1 billion in revenue this year due to the US-China tariff war and NIH funding cuts. Because of the "substantial" US tariff rates on ...
View ArticleBristol Myers Q1 earnings: Transition continues as drugmaker raises guidance
Bristol Myers Squibb’s evolution after sweeping cost-cutting measures kept chugging along as the company reported first-quarter earnings Thursday morning. While overall revenue declined by 6% to $11.2...
View ArticleVersant's latest biotech focuses on inflammatory diseases
Versant Ventures' biotech incubation team has launched another Swiss startup, this time focused on a pair of antibodies for autoimmune and inflammatory diseases. Granite Bio broke cover on Thursday...
View ArticleAvidicure's $50M seed round; Flagship's new AI company that detects disease
Plus, news about Novo Holdings, Bioxodes and Tempus AI: Dutch biotech raises $50M in seed funding: Avidicure, which is developing avidity engineered antibodies for cancer, said it plans to use the...
View ArticleLotte Bio launches ADC services; Ypsomed to focus on self-injection business
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lotte Biologics has launched its ADC services and it has signed its ...
View Article